Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | GCK | P35557 | 13/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655275 | 0.85 | GCK (0.43) | GCKMAPK1LMNAKDM4EALDH1A1 | |
| SCHEMBL12579150 | 0.83 | CA12 (0.44) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1040920 | 0.82 | GCK (0.54) | GCK | |
| SCHEMBL2659188 | 0.81 | GCK (0.42) | GCKMAPK1LMNA | |
| SCHEMBL2086782 | 0.81 | GCK (0.65) | GCK | |
| SCHEMBL1040072 | 0.80 | GCK (0.55) | GCK | |
| SCHEMBL359969 | 0.80 | GCK (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1043065 | 0.78 | GCK (0.55) | GCK | |
| SCHEMBL1040935 | 0.78 | GCK (0.55) | GCK | |
| SCHEMBL2662299 | 0.78 | GCK (0.55) | GCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| US-7964725-B2 | Heteroarylbenzamide derivatives for use in the treatment of diabetes | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2272834-A1 | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| EP-2272834-A1 | Benzoyl amino heterocyclyl compounds as glucokinase (GLK) activators | AstraZeneca AB (SE) | 2011-01-12 | — | — | EP | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| US-7671060-B2 | Heteroaryl benzamide derivatives | ASTRAZENECA AB (SE) | 2010-03-02 | — | — | US | disclosed |
| EP-2078000-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | AstraZeneca AB (SE) | 2009-07-15 | — | — | EP | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| US-20080318968-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2008-12-25 | — | — | US | disclosed |
| WO-2008050117-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008050117-A1 | BENZOYL AMINO HETEROCYCLYL COMPOUNDS AS GLUCOKINASE (GLK) ACTIVATORS | ASTRAZENECA AB (SE) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318968-A1 | Chemical Compounds | GCKR, GCK, HK1 | CA12 4344/4885CA1 3275/4885CA2 1724/4885 |
| US-20100173825-A1 | HETEROARYL BENZAMIDE DERIVATIVES | GCK, GCKR, HK1 | CA12 4822/4885CA1 4611/4885CA2 2612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.